Evidence map›Paper›PMID 29858752›Full record

ArticleBreast cancer research and treatment2018

The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome.

H Arias-Pulido, A Cimino-Mathews, N Chaher, C Qualls, N Joste, C Colpaert, J D Marotti, M Foisey, E R Prossnitz, L A Emens and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer research and treatment, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed, 1 pooled it
4.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 1 synthesis or guideline pooled it, 81 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Reprogramming the Immune Landscape of Inflammatory Breast Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Immune Microenvironment in Breast Cancer Metastasis.Advances in experimental medicine and biology · 2025
    Review
  14. Understanding the role of TNFR2 signaling in the tumor microenvironment of breast cancer.Journal of experimental & clinical cancer research : CR · 2024
    Review
  15. Observational
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 3 countries.

H Arias-PulidoDepartments of Microbiology and Immunology, Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, 621 Rubin Building - HB7936; 1 Medical Center Drive, Lebanon, NH, 03756, USA. hugo.ariaspulido@dartmouth.edu.ORCID http://orcid.org/0000-0003-4941-1110
A Cimino-MathewsDepartments of Pathology, The Johns Hopkins University School of Medicine and Bloomberg-Kimmel Institute for Immunotherapy, Baltimore, MD, USA.
N ChaherDepartment of Pathology, Centre Pierre et Marie Curie et Faculté de Médecine d'Alger, Algiers, Algeria.
C QuallsDepartments of Pathology, Mathematics and Statistics, and Internal Medicine, The University of New Mexico Comprehensive Cancer Center, and Health Sciences Center, Albuquerque, NM, USA.
N JosteDepartments of Pathology, Mathematics and Statistics, and Internal Medicine, The University of New Mexico Comprehensive Cancer Center, and Health Sciences Center, Albuquerque, NM, USA.
C ColpaertDepartment of Pathology, Oncology Centre, GZA Hospitals, Iridium Cancer Net, Antwerp, Belgium.
J D MarottiPathology and Laboratory Medicine, and Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, NH, USA.
M FoiseyDepartments of Microbiology and Immunology, Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, 621 Rubin Building - HB7936; 1 Medical Center Drive, Lebanon, NH, 03756, USA.
E R ProssnitzDepartments of Pathology, Mathematics and Statistics, and Internal Medicine, The University of New Mexico Comprehensive Cancer Center, and Health Sciences Center, Albuquerque, NM, USA.
L A EmensDepartments of Oncology, The Johns Hopkins University School of Medicine and Bloomberg-Kimmel Institute for Immunotherapy, Baltimore, MD, USA.
S FieringDepartments of Microbiology and Immunology, Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, 621 Rubin Building - HB7936; 1 Medical Center Drive, Lebanon, NH, 03756, USA.
Dartmouth College · USUniversity of New Mexico · USBloomberg (United States) · USCentre de Recherche Nucléaire d’Alger · DZIridium Kankernetwerk · BE

Funding

Molecular Mechanisms and Applications of Novel ER/GPER-selective LigandsR01CA194496 · NCI · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI ARTERBURN, JEFFREY B, PROSSNITZ, ERIC R · 2016 to 2025
$4.1M
G protein-coupled estrogen receptor GPER and breast carcinogenesisR01CA163890 · NCI · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI PROSSNITZ, ERIC R · 2012 to 2023
$3.3M
National Institutes of Health CA163890NCI NIH HHS R01 CA163890NCI NIH HHS R01 CA194496
6 · The paper itself

Abstract

purposeThe purpose of the study was to evaluate protein expression of PD-L1 and CD20 as prognostic biomarkers of patient outcome in inflammatory breast cancer (IBC) samples.

methodsPD-L1 and CD20 protein expression was measured by immunohistochemistry in 221 pretreatment IBC biopsies. PD-L1 was assessed in tumor cells (PD-L1

resultsPD-L1

conclusionCD20

Indexed as

Antigens, CD20B7-H1 AntigenBiomarkersB-LymphocytesFemaleGene ExpressionHumansImmunohistochemistryInflammatory Breast NeoplasmsKaplan-Meier EstimateLymphocytes, Tumor-InfiltratingPrognosisProgrammed Cell Death 1 ReceptorTriple Negative Breast NeoplasmsAntigens, CD20B7-H1 AntigenBiomarkersCD274 protein, humanProgrammed Cell Death 1 ReceptorCD20Immuno-oncologyInflammatory breast cancerPatient outcomePD-L1Triple-negative

Identifiers

PMID29858752
PMCPMC6173952
OpenAlexW2806010665

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.